Evaluation of the use of in vitro methodologies as tools for screening new compounds for potential in vivo toxicity.
Luber-Narod
J
J
PharmaMar USA, Inc., 320 Putnam Avenue, Cambridge, MA 02139, USA. jlnarod@pharmamarusa.com
Smith
B
B
Grant
W
W
Jimeno
J M
JM
López-Lázaro
L
L
Faircloth
G T
GT
D000826:Animal Testing Alternatives; D000818:Animals; D001921:Brain / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D002460:Cell Line / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D047630:Depsipeptides; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D064420:Drug-Related Side Effects and Adverse Reactions; D015507:Drugs, Investigational / Q000633:toxicity*; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D051379:Mice; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D010455:Peptides / Q000633:toxicity; D051381:Rats; D012680:Sensitivity and Specificity; D013116:Spinal Cord / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D013778:Tetrazolium Salts / Q000378:metabolism; D018675:Toxicity Tests / Q000379:methods*
D047630:Depsipeptides; D015507:Drugs, Investigational; D010455:Peptides; D013778:Tetrazolium Salts; C097897:kahalalide F; D007770:L-Lactate Dehydrogenase